, made in response due to a “decades long decline” in Canada’s domestic biopharmaceutical industry which was highlighted during the COVID-19 pandemic when domestic vaccines were not able to be produced.
“This is why the federal government is working tirelessly to rebuild Canada’s domestic biomanufacturing sector by focusing on both quick strategic actions and a long-term vision,” a joint message from Canada’s federal ministers said in a release. “Canada’s strategy is already yielding results, as we have successfully supported investments that will add capacity across a range of vaccine platforms and production processes — like RNA vaccine development and production, protein-based vaccines, viral vector manufacturing capacity, and new fill and finish capabilities.
“The Immuno-Engineering and Biomanufacturing Hub is a testament to Canada’s commitment to innovation and collaboration and will position our country as a global leader in developing immune-based therapeutics,” said the Hon. Joyce Murray, Minister of Fisheries, Oceans and the Canadian Coast Guard. “With its seamless drug development pipeline, CIEBH will help ensure Canada is prepared to respond to future pandemics and health challenges with leading-edge homegrown solutions found right here at the University of British Columbia.”